TRIAL DETAIL
A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Completed |
|||
Phase: |
1 |
Start Date 06/01/2009 |
Age of Trial (yrs) 14.3 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
HSP90 inhibitor |
|||
Strategy: |
Destroy KIT |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
CHSP990A2101, EUDRACT number 2008-006440-19 |
|||
Sponsor: |
Novartis |
|||
Patient Contact: |
Novartis Pharmaceuticals
+1-800-340-6843 |
|||
Contact email: |
||||
Contact Phone: |
+1-800-340-6843 |
|||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
This study will study the safety, tolerability and metabolism of a drug called HSP990 when given by mouth once a week to subjects with advanced solid tumors. Prior treatment with any Hsp90 or HDAC inhibitor compound is an exclusion factor. |
|||
Trial Links |
Trial Results |
Drug Information |
| Novartis pipeline page |
| Vernalis pipeline page |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
Augusta |
GA |
30912 |
USA |
||
3322 West End Avenue |
Nashville |
TN |
37203 |
USA |
|
Toulouse |
31052 |
France |
|||
Toronto |
ON |
Canada |
|||
Barcelona |
08035 |
Spain |